Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study.
A prospective multicenter study of cryptococcal immune reconstitution inflammatory syndrome (IRIS) was conducted as a substudy of the Bacteriology and Mycology Study Group 3-01. Of 101 AIDS patients with cryptococcal meningitis who received highly active antiretroviral therapy (HAART), 13 experienced cryptococcal IRIS. No association between the timing of HAART initiation and the diagnosis of IRIS was identified. Increased baseline serum cryptococcal antigen (CrAg) titer was a risk factor for cryptococcal IRIS.
Sungkanuparph
Somnuek
S
Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand. rasuy@mahidol.ac.th
Filler
Scott G
SG
Chetchotisakd
Ploenchan
P
Pappas
Peter G
PG
Nolen
Tracy L
TL
Manosuthi
Weerawat
W
Anekthananon
Thanomsak
T
Morris
Michele I
MI
Supparatpinyo
Khuanchai
K
Kopetskie
Heather
H
Kendrick
Amy S
AS
Johnson
Philip C
PC
Sobel
Jack D
JD
Larsen
Robert A
RA
D017088:AIDS-Related Opportunistic Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D000666:Amphotericin B / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000946:Antigens, Fungal / Q000097:blood; D023241:Antiretroviral Therapy, Highly Active; D017322:Clinical Trials, Phase II as Topic; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D016867:Immunocompromised Host; D015994:Incidence; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D016919:Meningitis, Cryptococcal / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D016016:Proportional Hazards Models; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors
D019380:Anti-HIV Agents; D000935:Antifungal Agents; D000946:Antigens, Fungal; D000666:Amphotericin B; D015725:Fluconazole